Quick Take
Arcutis Biotherapeutics (ARQT) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The company is advancing a pipeline of drug treatment candidates for various chronic skin conditions.
ARQT is in Phase 3 trials for its lead candidate and expects topline data readout in 2021 for its most advanced programs.
I’ll provide an update when we learn more about the IPO’s valuation and pricing assumptions.
Company & Technology
Westlake Village, California-based Arcutis was founded to develop treatment for psoriasis and dermatitis